Psilocybin-assisted therapy for major depressive disorder.
Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis.
AI Summary
Key Findings
Abstract
OBJECTIVE: This systematic review and meta-analysis of six randomized controlled trials aimed to investigate the temporal changes in the efficacy and safety of psilocybin treatment for major depressive disorder (MDD). METHODS: Separate meta-analyses were conducted for standard-dose psilocybin (25 mg/session, or 20-30 mg/70 kg/session) and low-dose psilocybin (10 mg/session or 15.05 mg/70 kg/session) subgroups. Control conditions included placebo, waiting-list control, niacin, or psilocybin 1 mg. RESULTS: Standard-dose psilocybin was superior to control in reducing depressive symptoms (standardized mean difference [SMD]: -1.05; 95% confidence intervals [CIs]: -1.60 to -0.50, p = 0.0002, I = 75%, K = 4). Sensitivity analysis excluding studies with waiting-list controls supported the superiority of standard-dose psilocybin compared with control without considerable heterogeneity (SMD: -0.70; 95% CI: -1.03 to -0.36, p
Affiliation
Taro Kishi
External References
- PubMed ID:
- 41876058
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.